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BACKGROUND: Women’s awareness of ovarian cancer (OC) risks, their attitudes towards and beliefs about screening, together with
misunderstandings or gaps in knowledge, may influence screening uptake.
METHODS: In total, 21715 post-menopausal women completed questionnaires before randomisation into the UK Collaborative Trial
of Ovarian Cancer Screening.
RESULTS: In all, 42.3% correctly identified their lifetime risk of OC; 87.1% knew that a family history of OC increased risk, but only
26.7% appreciated the association with a family history of breast cancer. Although 38.2% acknowledged increased risk post-
menopause, only 8.8% were aware that OC diagnoses are highest in women over 65 years. Few (13.7%) recognised the association
between pregnancy and reduced OC risk or protective effects of breastfeeding (6.2%). There were common misconceptions; 37.2%
thought that an abnormal cervical smear and 26.4% that oral contraception increased the likelihood of OC. Although 84.4%
recognised that most ovarian masses are benign, 20.2% thought having had a benign cyst increased OC risk. Most (99.4%) believed
that a high uptake of OC screening would reduce mortality and (96.2%) that screen-detected cancers would have an improved
prognosis.
CONCLUSIONS: The results show a need for improved public understanding about OC risks and provide important information for
GPs and health educationalists about initiatives needed for future awareness, prevention and screening programmes.
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In 2007, 4317 UK women died from ovarian cancer (OC), the fifth
most common cancer in women (Cancer Research UK, 2009).
Earlier diagnosis is associated with improved prognosis, yet many
women present too late with advanced disease. The primary aim
of the UK Collaborative Trial of Ovarian Cancer Screening
(UKCTOCS) is the assessment of screening on mortality. The
resource implications, acceptance, physical and psychosocial
morbidity of screening are also being measured. In total, 202638
post-menopausal women from the general population aged
between 50 and 74 years have been recruited to the trial (Menon
et al, 2008, 2009). Women from 13 centres in England, Wales and
Northern Ireland were randomised into three groups: a no
intervention group control, multimodal screening (annual screen-
ing with serum CA125 followed by transvaginal ultrasound scan
as a second-line test) or annual transvaginal ultrasound. At trial
entry, participants were asked about their awareness of OC risk
factors and views about putative benefits of screening, to identify
possible misunderstandings or gaps in knowledge that might
influence willingness to adhere to screening. Such data are also
valuable for health education initiatives.
Little is known about the awareness of the risks of OC or views
about screening among women in the general population of
the United Kingdom, although a survey commissioned in 2007
by an OC charity and Dr Foster Intelligence suggested that 59%
of women were unaware of any risk factors associated with OC
(Dr Foster, 2007). Most published research has been carried out in
the United States (Andersen et al, 2002, 2004; Hensley et al, 2003;
Salsman et al, 2004; Lockwood-Rayermann et al, 2009), which
might not extrapolate to women in the United Kingdom. The
methodological inadequacies of some studies have been described
(Salsman et al, 2004). Furthermore, many reports have involved
women at high familial risk of OC (Wardle, 1995; Hensley et al,
2003; Andersen et al, 2004; Tiller et al, 2005) who may well have
different attitudes and beliefs to the general population. However,
findings to date suggest that screening attendees may overestimate
their OC risk (Andersen et al, 2002; Hensley et al, 2003) and that
this may be associated with psychological morbidity (Robinson
et al, 1997). Women may be unaware of links between breast
cancer and OC (Andersen et al, 2004) and may misunderstand the
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spurpose of screening (Brain et al, 2004). There may be confusion
between cervical cancer and OC screening (Black et al, 2007;
Lockwood-Rayermann et al, 2009) and a lack of understanding
about the fallibility of screening tests (Tiller et al, 2005; Editorial,
2009).
In this paper, we report the knowledge and pre-randomisation
beliefs of 21715 women participating in UKCTOCS regarding OC
risk, perceived risk factors, their attitudes towards screening and
the associations of all these with sociodemographic, psychological
characteristics and medical history.
MATERIALS AND METHODS
The design of the main UKCTOCS has been described in detail
(Menon et al, 2008, 2009). It has ethical approval from the
multicentre regional and local ethics committees, and all
participants signed a consent form. Between April 2001 and
October 2005, 91.6% (185693/202638) women provided separate
written informed consent to participate in the psychosocial arm of
the trial, which examined knowledge, beliefs and attitudes to
OC screening, together with psychological and sexual well being.
Before recruitment and questionnaire completion, participants
viewed an information DVD and participated in a group
discussion on the need for a randomised trial. Baseline ques-
tionnaires were completed after recruitment, but before randomi-
sation and returned to the psychosocial study centre by mail.
Owing to a variety of methodological, economic and practical
constraints, most previously reported research uses cross-sectional
analysis. Measurement of the psychosocial impact of trial
participation (which will be reported on trial completion)
necessitates a truly prospective, longitudinal study. Therefore,
two types of follow-up were initiated: first, the baseline data from a
random sample across all three UKCTOCS groups (two screening
and one control group) were automatically entered on a database
for longitudinal follow-up, and second, the baseline questionnaires
from the remaining participants were stored, but only entered onto
the database for longitudinal follow-up if women were recalled
during the trial for repeat tests or extra screens.
Sample
This paper describes data from pre-randomisation baseline
questionnaires about the attitudes and beliefs of 21715 women:
1445 randomly selected at the outset and 20270 who were recalled
for further tests (Figure 1). Thus, the majority of women described
in this paper were randomised to one of the two UKCTOCS
screening groups: 51.5% (11191) to the multimodal group, 44.6%
(9685) to the ultrasound group and the remaining 3.9% (839) to
the control group. It should be noted that all the data about risk
perception, attitudes and beliefs were provided at baseline before
randomisation and any recall.
Study measures
Participants completed sociodemographic and medical history
details and four questionnaires: (1) one (see Appendix B) probing
perceived OC risk, beliefs and attitudes about screening adapted
from a questionnaire used previously on breast cancer screening
(Fallowfield et al, 1990); (2) the Spielberger State/Trait Anxiety
Inventory (STAI) (Spielberger et al, 1983), to measure anxiety
proneness (trait anxiety); (3) the General Health Questionnaire
12 (GHQ-12) (Goldberg and Williams, 1988), a screening tool to
determine general psychiatric morbidity or emotional distress in
clinical settings or community studies and (4) Fallowfield’s Sexual
Activity Questionnaire (Atkins and Fallowfield, 2007). Highest
education level achieved, personal and family history of breast
cancer and OC and use of oral contraception were obtained from
the main UKCTOCS dataset.
Statistical analysis
Logistic regression was used for binary outcomes and proportional
odds logistic regression for ordinal outcomes. The proportional
odds logistic model assumes that, for any dichotomy of the ordinal
scale, all odds ratios of interest, comparing the odds of observing a
‘higher’ outcome between two groups, do not depend on the cut
point of the dichotomy. The multiple explanatory variables
included in these models were age group, education level, centre,
Total sample
n = 21955
Participants
randomly selected
for follow-up
n=1663
Participants for
follow-up after
recall
n=20292
Multimodal
n = 307
Ultrasound
n = 299
Control
n = 839
Multimodal
n = 10884
Ultrasound
n = 9386
Data analysed
n=1445
Data analysed
n=20270
Missing data
n =218 Missing data
 n =22
Figure 1 Sample description.
OC risk factors, beliefs and attitudes towards screening
L Fallowfield et al
455
British Journal of Cancer (2010) 103(4), 454–461 & 2010 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sanxiety level, poor psychological health, partnership status, family
history of OC (at least one relative: mother, daughter, sister,
grandmother, granddaughter, aunt), family history of breast
cancer (at least one relative: mother, daughter, sister, grand-
mother, granddaughter, aunt/more than one relative: mother,
daughter, sister, grandmother, granddaughter, aunt), personal
history of breast cancer and having used oral contraception.
Education level was categorised into three groups according to
the highest formal qualifications specified: tertiary education
(a university degree or a nursing/teaching qualification), second-
ary education (O-levels, A-levels or a clerical/commercial qualifi-
cation) and no formal qualifications specified. Anxiety level was
categorised in three groups: low, average and high. Low and high
anxiety were, respectively, defined as an STAI trait score lower or
higher than one s.d. from the mean score using the sample mean
(36.5) and s.d. (10.1). The GHQ score covariate was dichotomised
with a ‘case’ of probable psychological morbidity defined as a GHQ
score of 4 or more. The results are reported as odds ratios with
95% confidence intervals (CI). Reported results for all regression
models are adjusted for centre. Analyses restricted to the random
sample were undertaken, but no qualitative differences arose.
With such a large sample size, tests of the simple null hypothesis
of no effect because of an explanatory variable led to many
significant results. However, many of the estimated odds ratios,
significant at the 5% level are close to 1 and too small to be
of practical importance (Armitage et al, 2002, p. 91). Therefore,
comments are restricted to those estimated odds ratios, which are
over 1.5 or below 0.7, corresponding to an increase in odds of 50%,
and the equivalent decrease on a log scale. The limits of 1.5 and
0.7 were chosen arbitrarily before examination of trial results.
To avoid being overly restrictive, we have allowed ourselves some
leeway in borderline cases and cases of earlier interest.
RESULTS
Sociodemographic and psychological characteristics and
medical history
The sociodemographic and psychological characteristics of
participants, which were very similar in the random- and recall-
based samples and are shown in Table 1, suggest that they were
representative of the general population; 50.4% reported educa-
tional qualifications (O-levels and above), which compares with
48.4% of UK females in 2005 (aged 55–64) who have attained at
least upper secondary education (OECD, 2006). The mean STAI
trait anxiety score of 36.5 (s.d. 10.1) is lower than that of women
attending a familial OC clinic in Scotland (mean¼40.1, s.d.¼9.0)
(Cull et al, 2001), but similar to that in a UK study of women
‘at risk’ of developing breast cancer (Thirlaway et al, 1996). The
proportion of participants (14.2%) identified as ‘cases’ (GHQ-12
score X4) is similar to the 15% of ‘cases’ among females (16 years
or older) in England in 2003 (Prescott and Moody, 2004).
Perception of risk
When asked to estimate the lifetime risk of a woman in this
country getting OC, 42.3% (95% CI: 41.7–43.0) of the 21358
respondents gave the most accurate answer (1 in 70), whereas
50.1% underestimated the risk (1 in 500) and 7.6% overestimated
the risk (1 in 12). When asked to estimate their own lifetime risk of
developing OC, 38.9% (95% CI: 38.2–39.5) selected 1 in 100, 54.2%
of 21332 selected 1 in 500 and 6.9% selected 1 in 10. Estimation of
a higher level of personal risk was associated with a personal
history of breast cancer and a family history of OC and higher
anxiety levels (Table 2, column 1).
Just under half of 21379 respondents believed that they were
at higher risk of developing cancers other than OC (48.3%; 95%
CI: 47.6–49.0), and this was considerably more likely among
respondents with a personal or family history of breast cancer and
also associated with a higher level of education (Table 2, column 2).
The majority (84.4%; 95% CI: 83.9–84.9) of 21552 respondents
were aware that most ovarian lumps turn out to be cysts rather
than cancer and 13.8% did not know. Those who answered
correctly were more likely to be younger, more educated and less
anxious (Table 2, column 3).
Only 8.8% (95% CI: 8.4–9.2) of 21205 respondents were aware
that the chances of an ovarian lump being cancer are highest
in women aged over 65 years. Correct answers were mainly asso-
ciated with having a family history of OC, older age and tertiary
education (Table 2, column 4).
Knowledge of risk factors
Participants were given a list of factors and asked to select those they
thought were associated with an increased risk of developing OC
(Table 3). Most participants (87.1%) were aware that a family history
of OC was associated with an increased risk of developing the disease,
but only 26.7% knew of the increased risk associated with a family
history of breast cancer. Less than two-fifths acknowledged the
increased likelihood of developing OC after the menopause and few
recognised the association between pregnancy and reduced OC risk
or the protective effects of breastfeeding. A fifth associated having
breast cancer with increased risk. There were also misconceptions;
37.2% associated having an abnormal cervical smear with an
increased likelihood of developing OC. Over a quarter of the
participants mistakenly believed that taking the contraceptive pill
increases the risk, and a fifth believed a benign cyst increased the risk.
Younger participants, those with a higher level of education and
those with more than one relative with breast cancer had a better
awareness of these risk factors (Table 4). For younger participants
Table 1 Baseline characteristics of participants
Age (years) n¼21715
Median (range) 61 (50–74)
Mean 60.9
Partnership status % (n¼21506)
Partner 78.4 (16850)
No partner 21.6 (4656)
Highest educational qualification % (n¼20082)
O-level or equivalent 7.9 (1597)
A-level or equivalent 2.3 (457)
Clerical or commercial qualification 18.4 (3691)
Nursing or teaching 7.0 (1416)
College/university degree 14.8 (2963)
None specified/or stated none of the above 49.6 (9958)
STAI trait anxiety (minimum¼20, maximum¼80) % (n¼21211)
Low score (20–26) 16.7 (3547)
Average score (27–46) 66.0 (13989)
High score (47–80) 17.3 (3675)
GHQ 12 (minimum¼0, maximum¼12) % (n¼21598)
‘Case’ (score¼4 or more) 14.2 (3077)
Medical history % (n¼21692)
At least 1 relative
a with ovarian cancer 4.6 (999)
At least 1 relative
a with breast cancer 21.9 (4742)
Had breast cancer 4.0 (878)
Ever used oral contraception 58.7 (12735)
Abbreviations: GHQ¼General Health Questionnaire; STAI¼Spielberger State/Trait
Anxiety Inventory.
aRelatives specified: mother, daughter, sister, grandmother,
granddaughter, aunt.
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sand those with a higher level of education, this was mainly due to
their greater awareness of the risk of familial OC and the increase
in risk post-menopause. Those with a higher level of education
also had greater awareness of the protective effects of pregnancy
and breastfeeding. The significant odds ratio for those with
relatives with breast cancer was primarily due to a greater
awareness of the risks associated with having family members
with breast cancer and having had breast cancer.
Views on susceptibility and screening
A quarter of 21577 respondents (25.2%; 95% CI: 24.6–25.7) had
spoken to other members of their family about the risk of OC and
this was more likely among those with a family history of OC
than those without a family history (odds ratio: 2.76; 95% CI:
2.41–3.16). Participants were asked what they perceived to be the
costs and benefits of screening and for their views on their
susceptibility to OC (Table 5). The majority (99.4%) believed a
high uptake of OC screening would reduce mortality and (96.2%)
that screen-detected cancers would have an improved prognosis.
Witnessing friends or hearing of public figures getting OC
increased awareness of personal risk about developing OC for
84.8%. Only 15.2% said that coming for screening would cause
them to worry unnecessarily, but over two-thirds expressed
concerns about developing OC.
DISCUSSION
Principal findings
Just over two-fifths of the UKCTOCS participants had an accurate
awareness of lifetime population risk of OC, but half under-
estimated the risk. As far as personal risk was concerned, higher
levels of anxiety, a personal history of breast cancer or a family
history of OC were associated with a higher estimation.
With the exception of a family history of OC, there was a lack of
awareness regarding specific risk factors and there were some
common misconceptions. Only 26.7% knew of the increased risk of
OC associated with a family history of breast cancer. Only 38.2%
identified the increased likelihood of developing OC after the
menopause (this despite participating in a trial where menopausal
status was one of the eligibility criteria for OC screening) and
o1 in 10 were aware that the chances of an ovarian mass being
Table 2 Relationship between responses to questions regarding perception of risk
a and participants’ characteristics
Odds ratio (95% CI)
Covariate
Personal risk higher
(n¼19082)
Higher risk of other cancers
(n¼19112)
Ovarian lumps
(n¼19261)
Cancer risk by age
(n¼18965)
Age group
50–54 Reference
55–59 1.00 (0.92–1.09) 0.99 (0.91–1.08) 0.95 (0.84–1.09) 1.02 (0.86–1.22)
60–64 0.95 (0.87–1.04) 1.00 (0.91–1.09) 0.79 (0.69–0.90) 1.42 (1.20–1.69)
65–69 0.92 (0.84–1.01) 0.98 (0.89–1.08) 0.67 (0.58–0.76) 2.37 (1.99–2.81)
70–74 0.84 (0.75–0.94) 0.94 (0.83–1.06) 0.47 (0.41–0.55) 2.37 (1.94–2.89)
Education level
None specified Reference
Secondary 0.80 (0.75–0.86) 1.12 (1.05–1.20) 1.50 (1.36–1.65) 1.02 (0.90–1.16)
Tertiary 0.74 (0.69–0.80) 1.55 (1.44–1.68) 1.98 (1.76–2.22) 1.74 (1.54–1.96)
Anxiety (STAI trait score)
Low Reference
Average 1.27 (1.17–1.38) 1.19 (1.09–1.28) 0.88 (0.78–0.99) 0.96 (0.84–1.09)
High 1.81 (1.62–2.01) 1.39 (1.25–1.55) 0.62 (0.53–0.72) 0.96 (0.79–1.17)
GHQ case (vs non-case) 1.06 (0.96–1.16) 1.12 (1.02–1.23) 0.95 (0.84–1.08) 0.84 (0.70–1.00)
Partner (vs no partner) 0.99 (0.93–1.06) 0.99 (0.92–1.06) 1.01 (0.91–1.11) 0.97 (0.86–1.10)
Relative with ovarian cancer 1.94 (1.70–2.21) 0.90 (0.78–1.03) 0.82 (0.69–0.98) 1.46 (1.18–1.81)
One relative with breast
cancer
1.17 (1.09–1.26) 1.66 (1.54–1.79) 1.07 (0.97–1.20) 1.07 (0.94–1.21)
41 relative with breast
cancer
1.41 (1.22–1.63) 3.13 (2.65–3.70) 1.04 (0.84–1.29) 0.96 (0.73–1.25)
Had breast cancer 2.40 (2.09–2.77) 2.54 (2.16–2.99) 1.27 (1.02–1.59) 0.97 (0.75–1.25)
Ever used oral contraception 0.88 (0.83–0.94) 1.05 (0.98–1.12) 1.23 (1.13–1.35) 1.11 (0.99–1.24)
Abbreviations: CI¼confidence interval; GHQ¼General Health Questionnaire; STAI¼Spielberger State/Trait Anxiety Inventory.
aThe results correspond to a proportional
odds logistic regression of the probability of estimating a higher level of personal risk and logistic regressions for the probability of answering ‘yes’ to the question ‘Do you think
you are at higher risk of developing other cancers than ovarian cancer’ and the probabilities of being aware that most ovarian lumps turn out to be cysts and that the chances
of an ovarian lump being cancer are highest in women aged over 65 years, respectively.
Table 3 Women’s knowledge of risk factors
a
% Responding yes (95% CI)
(a) Has relatives with ovarian cancer 87.1 (86.7–87.6)
(b) Past menopause 38.2 (37.5–38.8)
(c) Has relatives with breast cancer 26.7 (26.1–27.3)
(d) Never pregnant 13.7 (13.3–14.2)
(e) Did not breastfeed 6.2 (5.8–6.5)
(f) Has had breast cancer 19.6 (19.1–20.1)
(g) Has had abnormal smear 37.2 (36.6–37.9)
(h) Took the pill 26.4 (25.8–27)
(i) Has had benign ovarian cyst 20.2 (19.7–20.8)
Abbreviation: CI¼confidence interval.
aThe questionnaire stated ‘A woman is more
likely to develop ovarian cancer if she: (tick any of these you think may apply).’ The
sample size is 21377. (a–e) are accepted risk factors, (f) is equivocal in the absence
of family history and (g–i) are not risk factors.
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scancer are highest in women older than 65 years. Few recognised
the association between lower parity and increased OC risk or the
protective effects of breastfeeding. Even more importantly, there
were mistaken beliefs; over a third associated having an abnormal
cervical smear with an increased likelihood of developing OC and
over a quarter of the participants believed taking the contraceptive
pill increases the risk of OC.
Despite the absence of data yet showing conclusive benefit of
OC screening, most participants believed that a high uptake of it
would reduce mortality and that screen-detected cancers would
have an improved prognosis. The recent campaigns and publicity
to improve awareness about the symptoms of OC are clearly
important as only 41.1% recognised that it might be possible to
identify symptoms sooner than waiting for screening.
Ultrasonography is an invasive procedure and more than half
(51.9%) of the participants felt that gynaecological examinations
were embarrassing, which might ultimately have an effect on
willingness to attend and acceptability of this form of screening.
Although approximately two-thirds were concerned about getting
OC, it was encouraging that few (15.2%) said that coming for
OC screening would cause them to worry unnecessarily.
Strengths and weaknesses of the study
The women participating in UKCTOCS were volunteers from the
1.2 million invited and their risk perceptions may reflect this bias.
Participants’ general knowledge of OC may also have been raised
due to pre-recruitment information. In addition, volunteers for
prevention or screening trials tend to be healthier and may be better
educated and of higher socioeconomic status than the general
population (Pavlik et al, 2000; Pinsky et al, 2007). Nevertheless, the
formal education qualifications and GHQ scores of the UKCTOCS
participants suggest that these volunteers are fairly representative
of the general population and anxiety levels were not especially
high. This may reflect the methods used in UKCTOCS: recruitment
by random invitation using participating local authorities’ registers
to select participants who are more representative of the general
population than those who self-refer through advertisements (Menon
et al, 2008, 2009). Therefore, the knowledge about OC and attitudes
of this large group of UK women, who were not at high familial risk
of the disease, is valuable for estimating awareness and misconcep-
tions among the general population.
When considering screening participation women need to consider
their own risk of developing OC, as there are potential costs as well
as benefits. The questionnaire asked about numeric estimates of
lifetime risk, but the interpretation of probability information, is
difficult (Woloshin and Schwartz, 1999; Lipkus, 2007) and it may be
unnecessary for women to be able to quote numeric lifetime risk, as
long as they understand the likelihood of developing OC compared
with other diseases. Other methods may elicit different estimates.
The risk factors included in the UKCTOCS questionnaire were
selected 410 years ago and other risk factors for OC have since
been described including obesity, current use of hormone replace-
ment therapy, infertility, perineal talc use and endometriosis.
Recent campaigns to increase OC awareness may also have
increased public understanding.
Interpretation
The results from UKCTOCS and other international studies
regarding the ability of screening to detect OC in time to provide
Table 4 Relationship between the number of correct responses
regarding risk factors
a and participants’ characteristics
Odds ratio (95% CI)
Covariate Number of correct risk factor responses
Age group
50–54 Reference
55–59 1.04 (0.97–1.13)
60–64 0.92 (0.85–1.00)
65–69 0.80 (0.74–0.87)
70–74 0.70 (0.63–0.77)
Education level
None specified Reference
Secondary 1.32 (1.24–1.40)
Tertiary 2.11 (1.97–2.25)
Anxiety (STAI trait score)
Low Reference
Average 0.97 (0.91–1.04)
High 0.82 (0.74–0.90)
GHQ case (vs non-case) 0.82 (0.76–0.89)
Partner (vs no partner) 1.02 (0.96–1.08)
Relative with ovarian cancer 1.15 (1.02–1.29)
One relative with breast cancer 1.28 (1.20–1.37)
41 relative with breast cancer 1.47 (1.29–1.68)
Had breast cancer 1.04 (0.91–1.19)
Ever used oral contraception 1.08 (1.02–1.15)
Abbreviations: CI¼confidence interval; GHQ¼General Health Questionnaire;
STAI¼Spielberger State/Trait Anxiety Inventory.
aProportional odds logistic
regression of the number of correct responses regarding risk factors (listed in
Table 3). Definition of correct responses: items (a–f) endorsed, items (g–i) not
endorsed. If no items were endorsed, (g–i) non-endorsements were excluded and
data treated as missing. Regression also adjusted for centre. Sample size¼19127.
Table 5 Attitudes to and beliefs about ovarian cancer and screening
N Agree (strongly/a little)
a (%) 95% CI
Views about ovarian cancer screening
If more women went for ovarian screening, there would be fewer deaths from ovarian cancer 21586 99.4 99.3–99.5
If I was found to have ovarian cancer by screening, the chances of it being cured are higher 21590 96.2 95.9–96.4
I find gynaecological examination an embarrassment 21526 51.9 51.3–52.6
If I look out for the symptoms of ovarian cancer, I might find something sooner than if I go for screening 21423 41.1 40.5–41.8
If a lump is found in your ovaries, it is usually too late to do anything. 21506 22.4 21.9–23.0
Coming for screening would/has only made me worry (unnecessarily) about ovarian cancer 21562 15.2 14.7–15.7
Views about susceptibility to ovarian cancer
Whenever I hear of a friend/relative or public figure getting ovarian cancer, I realise I could get it too 21522 84.8 84.3–85.2
The older I get, the more I think about the possibility of getting ovarian cancer 21474 53.3 52.6–53.9
There are so many things that could happen to me, it is pointless to worry about ovarian cancer 21478 36.2 35.6–36.8
My health is too good at present even to consider thinking that I might get ovarian cancer 21490 32.0 31.4–32.6
aQuestionnaire had four choices: agree strongly, agree a little, disagree strongly, disagree a little, which were dichotomised.
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streatment that might influence survival, the best screening method,
its acceptability to patients and other costs and benefits are still
awaited. If the data do support implementation, then information
including the risk perceptions of individuals who agree to OC
screening may be important to our understanding of factors that
motivate attendance, especially as there are reported inequalities
in the use of existing breast and cervical screening services
(Moser et al, 2009). Previous research suggests that OC screening
attendees may believe themselves to be at higher personal risk
of and worry more about the disease than others (Wardle, 1995;
Andersen et al, 2002). Half of the UKCTOCS participants
underestimated risk. At the same time, many thought that they
were susceptible: only 48% of the UKCTOCS participants believed
that they were at higher risk of developing cancers other than OC,
although this was a more common belief among those with a
higher level of education and those with a personal or family
history of breast cancer. Views about susceptibility to OC were
similar to those expressed in an earlier study among women
attending for breast cancer screening, as were perceptions about
the costs and benefits of screening (Fallowfield et al, 1990). Fewer
of the UKCTOCS participants than those in the breast cancer
screening study said that coming for screening had made them
worry about cancer. Nevertheless, approximately two-thirds were
concerned about getting OC. This seems excessive, considering the
actual likelihood of their developing the disease, but women’s
anxieties could be a reflection of their knowledge that survival
is often poor.
As all the UKCTOCS participants had volunteered for the study,
it is not surprising that most believed in the value of OC screening,
but the majority of participants also believed that an increase in
uptake would reduce mortality. This finding is perhaps surprising
as women had received a detailed information sheet on the pros
and cons of screening and had attended an information session
during recruitment, when they were informed that the primary aim
of UKCTOCS is to examine whether ovarian screening can reduce
mortality. The belief that screen-detected cancers would have a
better prognosis is perhaps more understandable given that this is
the underlying premise on which OC screening is based. These
beliefs highlight the importance of presenting balanced informa-
tion about the limitations as well as the benefits of screening,
which has been highlighted in recent controversies about breast
screening (Welch, 2009). However, even if balanced information
is provided, individuals may have selective recollection of this as
well as preconceived ideas about screening initiatives.
Implications for clinicians and policymakers
The 6-year UKCTOCS follow-up study will be able to examine
whether an underestimation of population risk leads to poorer
attendance for screening. As well as improving information about
OC risk and screening, more research needs to be performed on
ways of assisting comprehension and understanding.
If the risk of OC is underestimated in the general population,
campaigns should be encouraged to increase awareness. At the
same time, it is important that this should be put in perspective
and women should be aware that OC is only the fifth most
common cancer among women in the UK accounting for 5% of all
female cancers (Cancer Research UK, 2009). Specific information
to remove the confusion between cervical and ovarian screening
needs to be provided and the protective effects of oral contra-
ception should be emphasised. However, health educators do have
to consider the potential confusions that can easily occur, for
example oral contraception is associated with higher breast cancer
risk.
Although having more educational qualifications, a family
history of cancer and to some extent age were associated with
improved knowledge about specific aspects of OC, there was a low
level of awareness in general. Thus, the findings from this large
study of UK women show the urgent need for improved public
education about all aspects of OC. Opportunistic discussions with
women about OC when being seen by their primary care
physicians and information leaflets in appropriate settings may
all contribute. These results provide important information for the
development of awareness initiatives that might be needed for OC
prevention and for screening programmes, if they are adopted.
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Risk perceptions questionnaire
Please read the following statements and tick those you believe to be true about ovarian cancer 
1.  The chances of a woman getting ovarian cancer in her lifetime in this country are - 
  (please tick one)     
       About  1  in  500      
       About  1  in  70         
       About  1  in  12       
2.  Most ovarian lumps turn out to be 
  (please  tick  one)          
       C y s t s           
       C a n c e r        
       Don’t  know 
3.  The chances of an ovarian lump being cancer are highest in women aged - 
  (please tick one) 
       2 5 - 3 5         
       3 5 - 4 5         
       4 5 - 5 5         
       5 5 - 6 5         
       over  65         
4.  A woman is more likely to develop ovarian cancer if she - 
 (tick  any of these you think may apply) 
          has never been pregnant or had children     
       did  not  breast  feed        
       took  the  pill         
          has relatives with breast cancer           
       has  relatives  with  ovarian  cancer       
       is  past  the  menopause       
       has  had  breast  cancer       
          has had a benign cyst in the ovary       
       has  had  an  abnormal  cervical  smear     
5.  What do you think is your lifetime risk of developing ovarian cancer? 
       1  in  10  chance      
          1 in 100 chance               
          1 in 500 chance         
6. Have you spoken to other members of your family about the risk of ovarian cancer? 
                          Yes      No 
7. Do you think you are at higher risk of developing other cancers than ovarian cancer? 
                  Y e s          N o    
strongly agree a disagree strongly
agree little a little disagree
8.  If more women went for ovarian screening there would  
  be fewer deaths from ovarian cancer     
9.  My health is too good at present even to consider thinking   
  that I might get ovarian cancer           
10.  If a lump is found in your ovaries it is usually too late     
  to do anything about it              
11.  Whenever I hear of a friend/relative or public figure     
  getting ovarian cancer I realise I could get it too       
12.  If I look out for the symptoms of ovarian cancer I might     
  find something sooner than if I go for screening       
13.  There are so many things that could happen to me that     
  it is pointless to think about ovarian cancer        
14.  Even though it is a good idea, I find gynaecological       
  examination an embarrassment             
15.   The older I get the more I think about the possibility       
  of getting ovarian cancer               
16.  Coming for screening would/has only made me worry       
  (unnecessarily) about ovarian  cancer      
17.  If I was found to have ovarian cancer by screening       
  the chances of it being cured are higher       
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